Plain-English translation of NCT07188077 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is trying to better understand primary central nervous system lymphoma (a rare blood cancer that develops in the brain) by comparing blood samples and immune markers from three groups: people newly diagnosed with brain lymphoma, people with lymphoma in other parts of the body, and healthy volunteers. The researchers hope that by studying these biological differences, they can find better ways to diagnose and treat brain lymphoma in the future.
Brain lymphoma is rare and hard to diagnose, and doctors need better tools to tell it apart from lymphoma in other parts of the body. This study aims to discover biological markers that could help doctors identify and understand brain lymphoma more quickly and accurately.
You likely qualify if…
You likely don't qualify if…
If you join this study as a patient with brain lymphoma, you will donate blood samples at the beginning and then return every 3 months for follow-up visits and additional samples — or sooner if you develop new symptoms. The study will also collect your imaging scans and biopsy results. If you are in the comparison group (either someone with lymphoma elsewhere or a healthy volunteer), you will likely have a single visit to provide baseline blood samples and information.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China